These Regulations relate to the additional relief for research-and-development-intensive, loss-making small or medium-sized enterprises under Chapter 2 of Part 13 of the Corporation Tax Act 2009 (“CTA 2009”) as it applies in relation to accounting periods beginning on or after 1st April 2024. They provide for specific rules to apply to companies with a registered office in Northern Ireland in two ways. First, payments by such companies for R&D undertaken outside the United Kingdom will qualify for Chapter 2 relief without the company having to show that special circumstances exist (of the sort referred to in section 1138A(2) and (3) of CTA 2009). Second, the additional benefit obtained by such companies from claiming Chapter 2 relief instead of R&D expenditure credit (under Chapter 1A of Part 13 of CTA 2009) will not exceed £250,000 over any 3-year period. These provisions take account of the specific market conditions in Northern Ireland. The limit on relief will protect against the fiscal risk from the more generous treatment of overseas expenditure.